Titration of serum CEA, p53 antibodies and CEA-IgM complexes in 142 patients with colorectal cancer and 150 healthy blood donors

Taiki Kojima, Takanori Matsui, Yasunobu Fujimitsu, Hiroshi Kojima, Hayato Uno, Kazuhiro Hiramatsu, Hitoshi Inagaki, Kazushige Oda, Akiharu Ishiyama, Naoki Iwata, Goro Nakayama, Yasuhiro Kodera
2011 Annals of Cancer Research and Therapy  
The early detection of colorectal cancer is important issue for improving the survival rate. Although fecal occult-blood testing and Carcinoembryonic antigen (CEA) in serum is widely used for noninvasive screen method, it has limited sensitivity. Methods: 142 patients with primary colorectal cancer who underwent surgery and 150 healthy volunteers were enrolled in this study. 37 of the tumors (26%) were Stage I, 34 (24%) were Stage II, 58 (41%) were Stage III, 12 (9%) were Stage IV. In each
more » ... sample, CEA, p53 antibodies, and CEA-IgM complexes were measured. Results: The diagnostic sensitivity with CEA (cut-off: 5 ng/ml) and p53 antibodies (cut-off: 3.0 U/ml) was 48% (68/142), Stage I 16% (6/37), Stage II 56% (19/34), Stage III 53% (31/58), and Stage IV 92% (12/13), while false positive rate was 7% (10/150). Because the sensitivity of CEA-IgM (cut-off: 150 AU/ml) was low, three tests combination did not much increase the overall sensitivity. Conclusions: The sensitivity of CEA-IgM for detecting colon cancer was lower than expected from previous study. As for the specificity of p53-antibodies, because its sensitivity is preserved with cut-off at 3.0 U/ml, re-evaluation of present cutoff level (1.3 U/ml) seemed to be needed.
doi:10.4993/acrt.19.15 fatcat:frf6fkin2rg6bhkn3k2sgxe7o4